Lineage Cell Therapeutics
LCTX
LCTX
115 hedge funds and large institutions have $192M invested in Lineage Cell Therapeutics in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 35 reducing their positions, and 14 closing their positions.
Holders
115
Holders Change
–
Holders Change %
0%
% of All Funds
2.02%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
15
Increased
27
Reduced
35
Closed
14
Calls
$1.49M
Puts
$617K
Net Calls
+$874K
Net Calls Change
+$570K
Top Buyers
| 1 |
1
State Street
Boston,
Massachusetts
|
$13.8M |
| 2 |
2
Wells Fargo
San Francisco,
California
|
$1.78M |
| 3 |
3
JPMorgan Chase & Co
New York
|
$5.58M |
| 4 |
4
UBS Group
Zurich,
Switzerland
|
$523K |
| 5 |
5
Rafferty Asset Management
New York
|
$488K |
Top Sellers
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
CFGS
126
Concourse Financial Group Securities
Birmingham,
Alabama
| – | – | – | – |
|
|
HT
127
HAP Trading
New York
| – | – | – | – |
|
128
AssetMark Inc
Concord,
California
| $0 | 9 | – | – |
|
|
LC
129
Lindbrook Capital
Calabasas,
California
| $0 | 29 | – | – |
|
|
CTC
130
Central Trust Company
Jefferson City,
Missouri
| $0 | 29 | – | – |
|
|
FWM
131
Focused Wealth Management
Newburgh,
New York
| $0 | 8 | – | – |
|